Abstract:Ubiquitin-proteasome system (UPS) is a major pathway for intracellular protein degradation. Its target proteins include a broad array of regulatory proteins that play important roles in cell cycle progression, cell development and differentiation, DNA damage responses, and tumorgenesis. Dysfunction of UPS gives rise to various kinds of diseases including infectious diseases, autoimmune diseases and cancers. The ubiquitylation process carries out by three classes of enzymes, E1 (activating enzyme), E2 (conjugating enzyme) and E3 (ubiquitin ligase). The ubiquitin is activated by E1 in an ATP-dependent manner, and then transferred to E2, and finally E3 adds ubiquitin on a target protein covalently as a tag, which can be recognized by proteasome for degradation. The regulation of UPS is rather complicated. Human genome encodes hundreds of E3 ligases super family, which are responsible for specificity of protein degradation. Cullin-RING ligases (CRLs) are the largest family of E3 ubiquitin ligases, which have essential role in controlling numerous cancer-relevant proteins ubiquitylation and proteasomal degradation1. Therefore, UPS becomes potential drug target for ant-tumor medication. The proteasome inhibitor, bortezomib, has been used to treat multiple myeloma and mantle cell lymphoma with great success both clinically and commercially for 5 years. However, as bortezomib targets all ubiquitin-tagged proteins, lacking of substrate specificity may cause many side effects. A series of recently published articles have reported a promising anti-tumor candidate, called MLN4924, which is a small-molecule selective inhibitor of NEDD8-activating enzyme (NAE)2. NAE, a heterodimer of NAEα and NAEβ, adenylates a small ubiquitin-like protein NEDD8 at its C-terminus in an ATP-dependent manner as the first step in the neddylation cascade, and transfers NEDD8 to UBC12. Then, NEDD8 is conjugated to cullin protein on CRLs. This covalent modification actives cullin complex to recruit an ubiquitin-charged E2 and leads to downstream target protein polyubiquitination and proteasomal degradation. MLN4924, which can form a covalent adduct with NEDD8, and block NAE at the first step in this pathway, has shown anti-tumor activity in many kinds of cancer cell lines and xenograft models, including lung cancer, colon cancer, melanoma and lymphoma (Figure 1). The anti-tumor activity of MLN4924 results from inactivation of CLRs, which causes DNA re-replication and inhibition of nuclear factor (NF)-κB signaling, thus leading to cancer cell death3. MLN4924 is currently in clinical trials, and its safety for human and clinical activity has been confirmed in both solid tumor and hematologic malignancy. However, the resistance to the agent was also reported in some studies. Early in 2012, researchers found that treatment-emergent heterozygous mutations in the ATP binding pocket and NEDD8-binding cleft of NAEβ were responsible for the resistance to MLN4924 in cell line and xenograft models of cancer4. However, the genetic determinants responsible for the sensitivity to MLN4924 are not clear. Further study showed that more than 100 genes contributed to the sensitivity to MLN4924, and approximately a half of them interfered with components of cell cycle, apoptotic machinery, UPS and DNA damage responses. Among them, the genes involved in DNA replication, P53, BRCA1/BRCA2, transcription-coupled repair and base excision repair appeared to be important for the lethality of MLN4924. In colon cancer cells, the genes of G2/M checkpoint affected the sensitivity to MLN4924. Surprisingly, the p21-dependent intra-S-phase checkpoint and extensive re-replication play an essential role in this process5. These investigations on the efficacy of MLN4924 and the genes related to its resistance give us a clearer picture of this potential anti-tumor agent, and fill the gap from bedside to bench work.

A Small Molecule Inhibitor of the UBE2F-CRL5 Axis Induces Apoptosis and Radiosensitization in Lung Cancer

Discovery of a small molecule inhibitor of cullin neddylation that triggers ER stress to induce autophagy

Targeting Neddylation Pathways to Inactivate Cullin-RING Ligases for Anticancer Therapy

The Nedd8-activating Enzyme Inhibitor MLN4924 (Tak-924/Pevonedistat) Induces Apoptosis Via C-Myc-noxa Axis in Head and Neck Squamous Cell Carcinoma.

Data from The Nedd8-Activating Enzyme Inhibitor MLN4924 Induces Autophagy and Apoptosis to Suppress Liver Cancer Cell Growth

Overactivated neddylation pathway as a therapeutic target in lung cancer

Discovery of a small molecule targeting ULK1-modulated cell death of triple negative breast cancer in vitro and in vivo

Discovery of small molecule inhibitors of neddylation catalyzing enzymes for anticancer therapy

Suppression of tumor angiogenesis by targeting the protein neddylation pathway.

Identification of novel benzoyl hydrazine derivatives as activators of neddylation pathway to inhibit the tumor progression in vitro

Radiosensitization of Cancer Cells by Inactivation of Cullin-Ring E3 Ubiquitin Ligases

Targeting Cullin-RING Ligases by MLN4924 Induces Autophagy Via Modulating the HIF1-REDD1-TSC1-mTORC1-DEPTOR Axis.

The P21-Dependent Radiosensitization Of Human Breast Cancer Cells By Mln4924, An Investigational Inhibitor Of Nedd8 Activating Enzyme

Induction Of Protective Autophagy In Cancer Cells By Nae Inhibitor Mln4924

Protein Neddylation in Lung Tumorigenesis: Target Validation and Targeted Therapy

Induction of NEDD8-conjugating enzyme E2 UBE2F by platinum protects lung cancer cells from apoptosis and confers to platinum-insensitivity

Ubiquitin-proteasome system, a new anti-tumor target

A first-in-class inhibitor, MLN4924 (pevonedistat), induces cell-cycle arrest, senescence, and apoptosis in human renal cell carcinoma by suppressing UBE2M-dependent neddylation modification

Protein Neddylation and Its Alterations in Human Cancers for Targeted Therapy.

Inactivation of the Cullin (CUL)-RING E3 Ligase by the NEDD8-activating Enzyme Inhibitor MLN4924 Triggers Protective Autophagy in Cancer Cells

SOMCL-19-133, a novel, selective, and orally available inhibitor of NEDD8-activating enzyme (NAE) for cancer therapy